.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Julphar
Colorcon
Dow
Mallinckrodt
Queensland Health
Fuji
McKinsey
Farmers Insurance
Fish and Richardson

Generated: December 17, 2017

DrugPatentWatch Database Preview

STAXYN Drug Profile

« Back to Dashboard

Which patents cover Staxyn, and what generic alternatives are available?

Staxyn is a drug marketed by Bayer Hlthcare and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty-nine patent family members in fifty-four countries.

The generic ingredient in STAXYN is vardenafil hydrochloride. There are five drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the vardenafil hydrochloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer HlthcareSTAXYNvardenafil hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL200179-001Jun 17, 2010RXYesYes► Subscribe► SubscribeY► Subscribe
Bayer HlthcareSTAXYNvardenafil hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL200179-001Jun 17, 2010RXYesYes► Subscribe► Subscribe► Subscribe
Bayer HlthcareSTAXYNvardenafil hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL200179-001Jun 17, 2010RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for STAXYN

Drugname Dosage Strength RLD Submissiondate
vardenafil hydrochlorideOrally Disintegrating Tablets10 mgStaxyn12/22/2011

Non-Orange Book Patents for Tradename: STAXYN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,566,360 2-phenyl substituted imidatriazinones as phosphodiesterase inhibitors► Subscribe
7,314,8712-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension► Subscribe
7,704,9992-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
7,122,5402-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
6,890,922 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: STAXYN

Country Document Number Estimated Expiration
Russian Federation2423970► Subscribe
Japan3356428► Subscribe
South Korea20040014591► Subscribe
Australia738675► Subscribe
Turkey200001338► Subscribe
Israel163475► Subscribe
Bulgaria65257► Subscribe
China102198140► Subscribe
World Intellectual Property Organization (WIPO)2006092207► Subscribe
Hong Kong1031730► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Chubb
Teva
Cipla
Queensland Health
US Department of Justice
Argus Health
Dow
US Army
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot